Feb 4, 2025 · At Pfizer, we believe that everyone should have the same opportunity to access the latest advances in cancer care, regardless of their background or where they live.

Feb 4, 2025 · Pfizer delivered strong fourth quarter and full-year 2024 financial results, demonstrating the company’s continued focus on commercial execution. Full-year 2024 revenues were $63.6 billion, representing 7% year-over-year operational growth, while fourth-quarter revenues were $17.8 billion, reflecting 21% year-over-year operational growth.

We’ve transformed growth and development at Pfizer to ensure that everyone can follow a path to their dream career, whether that’s climbing a traditional ladder or “zig-zagging” their way to a new role.

We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today.

Pfizer purchases a nearby vacant ice plant, and employees work around the clock to convert it and perfect the complex production process. In just four months, Pfizer is producing five times more penicillin than originally anticipated. Penicillin is a turning point in human history—the first real defense against bacterial infection. Collapse

El 18 de noviembre, Pfizer y BioNTech anunciaron que, después de realizar el análisis de eficacia final en su ensayo clínico de fase 3 en curso, la vacuna COVID-19 basada en ARNm cumplía con todos los criterios de valoración de eficacia primarios del estudio.

Feb 2, 2025 · A Message from Pfizer CEO Albert Bourla: 2024 marks a significant year for Pfizer as we celebrate our 175th anniversary. That’s 175 years of unwavering commitment to advancing global health and making a lasting impact on society.

Oct 29, 2024 · At Pfizer our biotechnology is our foundation. With 25,000 clinical researchers testing everyday, pharmaceutical development and innovation are our focus. Learn more.

Feb 29, 2024 · We're elevating our breakthroughs in a bold new way on Pfizer.com. Check out our new visualized product pipeline, where you'll be able to take a deep dive into our working innovations and see where each product is in development!

Feb 3, 2025 · Pfizer will share these latest results with the FDA to potentially support full approval for BRAFTOVI in combination with cetuximab and mFOLFOX6 in patients with mCRC with a BRAF V600E mutation. The BREAKWATER data are also being discussed with other regulatory authorities around the world to support potential additional license applications ...